Pharmaceutical

STAT+: Do GLP-1s have a future treating alcoholism?

STAT+: Do GLP-1s have a future treating alcoholism?

Dec 3, 2023

Want to stay on top of the science and politics driving biotech today? Sign up t...

Navigating affordable approaches to cell therapy clinical trials

Navigating affordable approaches to cell therapy clinic...

Dec 2, 2023

By Luisa Sterkel & Joana Loureiro, Tenthpin Consultants and Dr. Frank Altznauer...

Biocon integrates Viatris biosimilars in 31 European countries

Biocon integrates Viatris biosimilars in 31 European co...

Dec 2, 2023

Biocon subsidiary Biocon Biologics has successfully integrated Viatris' biosimi...

AstraZeneca’s durvalumab recommended for bile duct cancers

AstraZeneca’s durvalumab recommended for bile duct cancers

Dec 2, 2023

The Scottish Medicines Consortium and the UK's National Institute of Health and...

FDA accepts Merck’s Keytruda plus Padcev sBLA to treat urothelial cancer

FDA accepts Merck’s Keytruda plus Padcev sBLA to treat ...

Dec 2, 2023

The US Food and Drug Administration (FDA) has accepted Merck (MSD)’s new supple...

Teva and Sanofi conclude collaboration deal for anti-TL1A therapy

Teva and Sanofi conclude collaboration deal for anti-TL...

Dec 2, 2023

Teva Pharmaceuticals and Sanofi have concluded a collaboration deal for co-deve...

Signal: Novo Nordisk sues more Florida pharmacies in battle against fake semaglutide

Signal: Novo Nordisk sues more Florida pharmacies in ba...

Dec 2, 2023

Novo Nordisk, manufacturer of blockbuster drugs Ozempic and Wegovy, announced W...

Partnership deals for psychedelic drugs take a trip with 500% surge in 2023

Partnership deals for psychedelic drugs take a trip wit...

Dec 2, 2023

Partnership deals involving psychedelic drugs saw a 500% growth in total deal v...

Phenomic scores two deals in two days with Boehringer and Astellas

Phenomic scores two deals in two days with Boehringer a...

Dec 2, 2023

Canada-based Phenomic AI has landed two strategic collaborations this week with...

FDA clears IND for Biora Therapeutics’s ulcerative colitis drug

FDA clears IND for Biora Therapeutics’s ulcerative col...

Dec 2, 2023

The US Food and Drug Administration (FDA) cleared Biora Therapeutics’s investig...

Orchard secures FDA fast track designation for Hurler syndrome gene therapy

Orchard secures FDA fast track designation for Hurler s...

Dec 2, 2023

Orchard Therapeutics will receive several expedited drug development benefi...

Johnson & Johnson bets heavy on AI-driven drug discovery

Johnson & Johnson bets heavy on AI-driven drug discovery

Dec 1, 2023

Want to stay on top of the science and politics driving biotech today? Sign up t...

STAT Virtual Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

STAT Virtual Event – Decoding Clinical Trials: Venture ...

Dec 1, 2023

Join STAT for a discussion with two VCs as they weigh in on what distinguishes g...

STAT+: Pharmalittle: Pfizer halts development of twice-daily obesity pill; Supreme Court to review Purdue bankruptcy deal

STAT+: Pharmalittle: Pfizer halts development of twice-...

Dec 1, 2023

Pfizer is stopping development of a twice-daily oral obesity medication after an...

Life-extending epilepsy surgery performed less often in Black children, study finds

Life-extending epilepsy surgery performed less often in...

Dec 1, 2023

Black children with drug-resistant epilepsy were less likely than white patients...

STAT+: Pfizer to halt development of its twice-daily oral obesity drug, following disappointing trial

STAT+: Pfizer to halt development of its twice-daily or...

Dec 1, 2023

Pfizer said Friday it was stopping development of a twice-daily oral obesity med...